medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2003, Number 1

<< Back Next >>

Ann Hepatol 2003; 2 (1)

Risk factors for liver fibrosis progression in patients with chronic hepatitis C

de Torres M, Poynard T

Language: English
References: 69
Page: 5-11
PDF size: 145.83 Kb.


Text Extraction

The major hepatological consequence of HCV infection is the progression to cirrhosis and its potential complications. Several factors have been clearly shown to be associated with fibrosis progression rate: duration of infection, age, male sex, consumption of alcohol, HIV coinfection and low CD4 count. As age and duration of infection increases, the risk of fibrosis increases and the impact of treatment (IFN) decreases. In conclusion, fibrosis progression has a progressive acceleration, sex, age and consumption of alcohol are strongly involved in this progression ; the possibility to assess with non-agressive biochemical markers the fibrosis stage will probably allow in the future to identify other factors related to fibrosis progression.


REFERENCES

  1. W.H.O. Hepatitis C: global prevalence. Wkly Epidemiol Rec 1997; 72: 341-4.

  2. Darby SC, Ewart DW, Giangrande PLF, et al. Mortality from liver cancer and liver disease in haemophilic men and boys given blood products contaminated with hepatitis C. Lancet 1997; 350: 1425-31.

  3. El-Serag HB, Mason A. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 34: 745-50.

  4. Deuffic S, Buffat L, Poynard T, Valleron AJ. Modeling the hepatitis C virus epidemic in France. Hepatology 1999; 29: 1596-601.

  5. Deuffic S, Poynard T, Valleron AJ. Correlation between HCV prevalence and hepatocellular carcinoma mortality in Europe. J Viral Hepatitis 1999; in press.

  6. Alter MJ, Kruszon-Moran D, Nainan OV et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556-562.

  7. Poynard T, Bedossa P, Opolon P, for the OBSVIRC, METAVIR, CLINIVIR and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349: 825-32.

  8. Sobesky R, Mathurin P, Charlotte F, et al. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. Gastroenterology 1999; 116: 378-386.

  9. Knodell KG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-435.

  10. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699.

  11. The METAVIR cooperative group. Inter- and intra-observer variation in the assessment of liver biopsy of chronic hepatitis C. Hepatology 1994; 20; 1: 15-20.

  12. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-93.

  13. Paradis V, Mathurin P, Laurent A, et al. Histological features predictive of liver fibrosis in chronic hepatitis C infection. J Clin Pathol 1996; 49: 998-1004.

  14. Yano M, Kumada H, Kage M, et al. The long term pathological evolution of chronic hepatitis C. Hepatology 1996; 23: 1334-40.

  15. Datz C, Cramp M, Haas T, et al. The natural course of hepatitis C virus infection 18 years after an epidemic outbreak of non-A, non-B hepatitis in a plasmapheresis centre. Gut 1999; 44: 563-67.

  16. Wiley TE, McCarthy M, Breidi L, McCarthy M, Layden TJ. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology 1998; 28: 805-9.

  17. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30: 1054-8.

  18. Bissell DM. Sex and Hepatic Fibrosis. Hepatology 1999; 29: 988-989.

  19. Poynter ME, Daynes RA. Peroxysome proliferator-activated receptor a activation modulates cellular redox status, represses nuclear factor-kB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem 1998; 273: 32833-41.

  20. Pol S, Fontaine H, Carnot, F et al. Predictive factors for development of cirrhosis in parenterally acquired chronic hepatitis C: a comparison between immunocompetent and immunocompromised patients. J Hepatol 1998; 29: 12-9.

  21. De Moliner L, Pontisson P, De Salvo GL, et al. Serum and liver HCV RNA levels in patients with chronic hepatitis C: correlation with clinical and histological features. Gut 1998; 42: 856-60.

  22. Roffi L, Ricci A, Ogliari C J, et al. HCV genotypes in Northern Italy: a survey of 1368 histologically proven chronic hepatitis C patients. J Hepatol 1998; 29: 701-6.

  23. Mathurin P, Moussalli J, Cadranel JF, et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 1998; 27: 868-72.

  24. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463-6.

  25. Consensus Statement. EASL International Consensus Conference on Hepatitis C. J Hepatol 1999; 30: 956-961.

  26. Pagliaro L, Peri V, Linea C, Camma C, Giunta M, Magrin S. Natural history of chronic hepatitis C. Ital J Gastroenterol 1999; 31: 28-44.

  27. Kenny-Walsh E, for the Irish Hepatology Research Group. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med 1999; 340: 1228-33.

  28. Datz C, Cramp M, Haas T, Dietze O, Nitschko H, Froesner G, Muss N, et al. The natural course of hepatitis C virus infection 18 years after an epidemic out break of non-A, non-B hepatitis in a plasmapheris centre. Gut 1999; 44: 563-7.

  29. Chossegros P, Pradat P, Bailly F, Chemello L, Sauleda S, Saracco G, Thursz M, et al. Natural history of chronic hepatitis C: fibrosis progression is not linear. J Hepatol 1999; 30 (suppl 1): 52.

  30. Observatoire National de l’Hépatite C. Groupe OBSVIRC. Observatoire national de l’hépatite C: bilan inital. Association Française pour l’Etude du Foie, Lyon 1994. (Abstract in: Gastroenterol Clin Biol 1995: 19-81).

  31. Cacoub P, Poynard T, Ghillani P, Charlotte F, Olivi M, Piette JC, Opolon P, for the Multivirc Group. Extrahepatic manifestations in patients with chronic hepatitis C. Rheum Arthr 1999; In Press.

  32. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426-32.

  33. Mc Hutchison J, Gordon S, Schiff E, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485-92.

  34. The METAVIR cooperative group. Inter- and intra-observer variation in the assessment of liver biopsy of chronic hepatitis C. Hepatology 1994; 20; 1: 15-20.

  35. Bedossa P, Poynard T for the METAVIR cooperative study group. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996; 24: 289-93.

  36. Tong MJ, Hwang SJ, Lefkowitz, et al. Correlation of serum HCV RNA and alanine aminotransferase levels in chronic hepatitis C patients during treatment with ribavirin. J Gastroenterol Hepatol 1994; 9: 587-91.

  37. Stuyver L, Rossau R, Wyseur A, et al. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993; 74: 1093-102.

  38. Poynard T, Bedossa P, Chevalier M, Mathurin P, Lemonier C, Trepo C, Couzigou P, Payen JL, Sajus M, Costa JM, Vidaud M, Chaput JC, and the multicentre study group. A comparison fo three interferon alpha-2b regimens for the long-term treatment of chronic non A, non B hepatitis. New Engl J Med 1995; 332: 1457-62.

  39. Fang JW, Albrecht JK, Jacobs S, Lau JY. Quantification of serum hepatitis C virus RNA. Hepatology 1999; 29: 997-8.

  40. Sobesky R, Mathurin P, Charlotte F, et al. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C : a dynamic view. Gastroenterology 1999; 116: 378-386.

  41. Deuffic S, Buffat L, Poynard T, Valleron AJ. Modeling the hepatitis C virus epidemic in France. Hepatology 1999; 29: 1596-601.

  42. Goodson JD, Taylor PA, Campion EW, et al. The clinical course of acute hepatitis in the ederly patient. Arch Intern Med 1982; 142: 1485-8.

  43. Wynne HA, Cope LH, Mutch E, et al. The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology 1989; 9: 297-301.

  44. Nagel JE, Chrest JJ, Adler HH. Enumeration of T lymphocytes by monoclonal antibodies in young age and aged humans. J Immunol 1991; 191: 151: 599-603.

  45. Makinodan T, Kay MMB. Age influence on the immune system. Adv Immunol 1980; 29: 287-91.

  46. Poynter ME, Daynes RA. Peroxysome proliferator-activated receptor a activation modulates cellular redox status, represses nuclear factor-kB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem 1998; 273: 32833-41.

  47. Yano M, Kumada H, Kage M, et al. The long term pathological evolution of chronic hepatitis C. Hepatology 1996; 23: 1334-1340.

  48. Roudot-Thoraval F, Bastie A, Pawlotsky JM, Dhumeaux D. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6.664 patients. The Study Group for the Prevalence and Epidemiology of Hepatitis C Virus. Hepatology 1997; 26: 485-90.

  49. Bissell DM. Sex and Hepatic Fibrosis. Hepatology 1999; 29: 988-989

  50. Yasuda M, Shimizu I, Shiba M, Ito S. Suppressive Effects of Estradiol on Dimethylnitrosamine-Induced Fibrosis of the Liver in Rats. Hepatology 1999; 29: 719-727.

  51. Ashcroft GS, Dodsworth J, van Boxtel E, et al. Estrogen accelerates cutaneous wound healing associated with an increase in TGF-beta1 levels. Nat Med 1997; 3: 1209-1215.

  52. Wang YJ, Wang SS, Bickel M, Guenzler V, Gerl M, Bissell DM. Two novel antifibrotics, HOE 077 and Safironil, modulate stellate cell activation in rat liver injury: differential effects in males and females. Am J Pathology 1998; 152: 279-287.

  53. Bentzen SM, Skoczylas JZ, Overgaard M, Overgaard J. Radiotherapy-related lung fibrosis enhanced by tamoxifen. J Nat Cancer Inst 1996; 88: 918-922.

  54. Roffi L, Ricci A, Ogliari C, Scalori A, Minola E, Colloredo G, et al. HCV genotypes in Northern Italy: a survey of 1368 histologically proven chronic hepatitis C patients. J Hepatol 1998; 29(5): 701-6.

  55. Pontisso P, Bellati G, Brunetto M, et al. Hepatitis C virus RNA profiles in chronically infected individuals: do they relate to disease activity? Hepatology 1999; 29: 585-9.

  56. Paradis V, Mathurin P, Laurent A, Charlotte F, Vidaud M, Poynard T, Hoang C, Opolon P, Bedossa P. Histological features predictive of liver fibrosis in chronic hepatitis C infection. J Clin Pathol 1996; 49: 998-1004.

  57. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001; 34(5): 730-9.

  58. Di Martino V, Lebray P, Moussalli J, Buffet C, Poynard T. Impact of pregnancies, oral contraceptives and menopause on HCV-related liver fibrosis progression. Hepatology 2001; 34(suppl): 222ª.

  59. Di Martino V, Rufat P, Boyer N, Renard P, Degos F, Martinot-Peignoux M, Matheron S, Le Moing V, Vachon F, Degott C, Valla D, Marcellin P. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology 2001; 34(6): 1193-9.

  60. Benhamou Y, Di Martino V, Bochet M, Colombet G, Thibault V, Liou A, Katlama C, Poynard T. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 2001; 34(2): 283-7.

  61. Pessione F, Ramond MJ, Njapoum C, Duchatelle V, Degott C, Erlinger S, Rueff B, Valla DC, Degos F. Cigarette smoking and hepatic lesions in patients with chronic hepatitis C. Hepatology 2001; 34: 121-125.

  62. Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, Khalil L, Turpin G, Opolon P, Poynard T. Liver fibrosis in overweight patients. Gastroenterology. 2000; 118(6): 1117-23.

  63. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, Ling MH, Albrecht J. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122(5): 1303-13.

  64. Hickman IJ, Clouston AD, Macdonald GA, Purdie DM, Prins JB, Ash S, Jonsson JR, Powell EE. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 2002; 51(1): 89-94.

  65. Hourigan LF, MacDonald GA, Purdie D, Whitehall V, Shorthouse C, Clouston A, Powell EE. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999; 29: 1215-1219.

  66. Freeman AJ, Dore G, Law MG, Thorpe M, Overbeck JV, Lloyd AR, Marinos G, Kaldor JM. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001; 34: 809-816.

  67. Deuffic-Burban S, Poynard T, Valleron AJ. Quantification of fibrosis progression in patients with chronic hepatitis C using a Markov model. J Viral Hepat 2002; 9: 114-22.

  68. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet. 2001; 7; 357(9262): 1069-75.

  69. Poynard T. The Liver Meeting, 53rd Annual Meeting of The American Association for the Study of Liver Diseases, Boston, Massachusetts, November 1-5, 2002, to appear.




2020     |     www.medigraphic.com